Q-Line Biotech Ltd IPO
Status: Closed
Overview
IPO date
21 May 2026 to 25 May 2026
Face value
₹ 10 per share
Price
₹ 326 to ₹343 per share
Issue Size
6,253,200 shares
(aggregating up to ₹ 214.48 Cr)
(aggregating up to ₹ 214.48 Cr)
Allotment Date
26 May 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Trading
Objectives of Q-Line Biotech Ltd IPO
Q-Line Biotech Ltd IPO Strategy
About Q-Line Biotech Ltd
Unlock Stock of the Month
T&C*
Strengths vs Risks of Q-Line Biotech Ltd
Know the pros & cons
Strengths
Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.- Diversified product portfolio with focus on IVD industry.
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Track record of healthy financial performance.
- Experienced Promoter and Management team.
Risks
- Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of the company raw materials, trade goods from its suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of the company products and has an adverse effect on the company business, financial condition, cash flows and results of operations.
- The company business is dependent on the sale of its products through distributors which also include the company group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of its products and could negatively impact the company business, results of operations, financial conditions and cash flows.
- The company is dependent on certain key suppliers to procure a significant portion of the company Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in its
operations, which could has an adverse effect on the company business, financial condition, results of operations and cash flows.
- The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operates the company business.
- For manufacturing of its machines and reagents, the company is dependent on the agreement with the European companies, any failures to renew the agreement or entering into the agreement on the terms which is not favourable for its may impact the company business operations, financial condition and cash flows.
- The company erstwhile associate company i.e. POCT Science House Private Limited and its promoters namely Saurabh Garg and Amita Garg has been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect the company financial condition.
- The company operations is concentrated in North India, and any loss of business in such region could has an adverse effect on the company business, results of operations and financial condition.
- The Company requires a significant amount of working capital for continuing growth. Its inability to meet the company working capital requirements may adversely affect its results of operations.
- The company is subject to risks arising from exchange rate fluctuations.
- The company has experienced negative cash flows from operating activities in the last three Fiscal years and may continue to has negative cash flows in the future which could has an impact on the company business and operations.
- Fluctuations in interest rates could adversely affect the company results of operations.
- The company depends on a limited number of customers for its revenue from operations, the loss of any of these Customers individually or severally could has a material adverse effect on the company business, operations and could has impacted the company financial strength.
- The company has in the past entered into related party transactions and may continue to does so in the future.
- The company work on government tender/agreements/commitment basis with its customers who purchase or place orders with the company, also its has price agreements with the company customers. If its customers select some other vendors/competitors for their requirement, it may has adverse effect on the company business.
- The Company is governed by stricter laws for manufacturing, subject to Clinical Validation and Accuracy, research & Development for their product and services, any failures to comply with these norms and regulations could affect the company ability to effectively manufacture, test and market its products, which may has an adverse effect on the company business, results of operations and financial condition.
- The company inability to meet its obligations, including financial and other covenants under the company debt financing arrangements could adversely affect its business, financial condition, cash flows and results of operations.
- There is certain discrepancies/errors/ non-compliances noticed in some of the company corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 1956/2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate and other law could impact the reputation and financial position of the Company to that extent.
- The company is exposed to the high holding period for debtors for the finished goods supplied which can impact its working capital requirement and also impacts the company cash flows.
- Any fault or inadequacy in the company quality control, not maintaining quality standards or default in manufacturing processes may damage its reputation, business operations and may subject the company to regulatory action and expose its to litigation or other liabilities.
- The company ability to access capital at attractive costs depends on its credit ratings. Non-availability of credit ratings or a poor rating may restrict the company access to capital and thereby adversely affect its business, financial conditions, cash flows and results of operations.
- The company Promoters will be able to exercise significant influence and control over its after the Offer and may has interests that are different from or conflict with those of the company other shareholders.
- Certain of the company shareholders, Directors, Key Management Personnel and Senior Management may be interested in its Company other than in terms of remuneration and reimbursement of expenses. The company Promoters, Directors and some of its Key Managerial Personnel may has interest in entities, which are in businesses similar to the company and this may result in conflict of interest with its.
- Some of the company business operations is being conducted on leased / rented, sub lease and leave license basis. The company inability to seek renewal or extension of such leases may materially affect its business operations.
- The company inability to protect or use its intellectual property rights or comply with intellectual property rights of others may adversely affect the company business and results of operations.
- The company operations depends on the availability of skilled employees, machine operators, scientist and technicians with expertise in healthcare sector. Inability to attract or retain such personnel may affect manufacturing, R&D process which may impact financial condition, cash flow and future growth.
- The company insurance coverage may not be adequate to protect its against certain operating hazards and this may have a material adverse effect on the company business and financial conditions.
- The company business may be adversely affected by international sanctions, changes in trade policy or the imposition of non-tariff barriers, which could impact its operations and exports.
- The company has encountered challenges in meeting the designated timelines for filing statutory returns, which may subject its to penalty under the relevant laws.
- The company is exposed to risk related to disposal of the company used products, if its is not able to dispose these as per the regulatory requirement the company may faces sanctions, restrictions which may lead to loss, unstable financial position, interrupted business operation or suspension of licences.
- Any failures on the company part to effectively address investor complaints or grievances in a timely manner may expose its to regulatory action and adversely affect the company reputation, business and financial condition.
- The company Subsidiaries/Associate, Q-line Innovations Private limited and Q-line IRIS Private limited has incurred losses in Fiscal 2025, 2024 and Fiscal 2023, respectively, and may does so in the future, which could have a material adverse effect on the company business, prospects, financial condition, cash flows and results of operations.
- The company inability to accurately forecast demand for its products and manage the company inventory may has an adverse effect on its business, financial condition, cash flows and results of operations.
- The company may faces pricing pressure from its competitors, local or state government as a result of low-cost alternative products in the market, Implementation of pricing policies by the Government or other authorities at lower price that its will be able to respond adequately to such pricing pressure.
- The company inability to successfully implement some or all its business strategies in a timely manner or at all could have an adverse effect on its business.
- Delay in delivering or failures in the performance of the company contracts for whatsoever reason with its customers for supply of the company products and machines, whether on its part or on the part of carrying and forwarding ("C&F") agents, may adversely affect the company business.
- If the company fail to retain its existing or acquire additional customers in a cost-effective manner, the company business, financial condition and results of operations could be adversely affected. Further, if its try to pass on the increased costing to the company customers, its customers may choose the company competitors over its.
- The company is appointing contract labour for carrying out certain of its operations in the department of manufacturing, administration and others for which the company may be held responsible for payment of their salary and wages and statutory dues and its may also incur some legal charges if the contractor with whom the company has appointed the labour fails to pay such charges and obligations which could have an adverse effect on the company financial condition, results of operations and cash flows.
- If the company is unable to establish and maintain an effective internal controls and compliance system, its business and reputation could be adversely affected.
- Breakdown, mishaps or accidents could result in a loss or slowdown during transportation and could also cause damage to life and property.
- The company products may not provide proper results if the reagent is not as per the quality standard or the machinery is not functioning properly or for any other reasons, which may affect adversely its business operations, cash flow and profitability.
- Any actual or perceived cybersecurity, data or privacy breach could interrupt the company operations and adversely affect its reputation, brand, business, financial condition and results of operations.
- The "Q-line" brand, is critical to the company ability to acquires new users and grow its business. If the company is not able to maintain its brand or reputation the company operations could materially and adversely affect user acceptance of its platform and the company operations
- Information relating to the installed manufacturing capacity, actual production and capacity utilization of the company manufacturing facilities included in this Red Herring Prospectus is based on various assumptions and estimates and future production and capacity may vary.
- The company business is dependent on the volume of the goods its sell to achieve the optimum level of profits, if the company is not able to achieve the volumes its will end up incurring losses on account of fixed cost.
- The company is dependent on third parties for the supply of utilities, such as water, gas and electricity, at its manufacturing facilities and any disruption in the supply of such utilities could adversely affect its manufacturing operations.
- Unsecured loans taken by the company/ its Subsidiaries/ Associates can be recalled at any time.
- The Company is party to certain legal proceedings, any adverse decision in such proceedings may has a material adverse effect on its business, results of operations and financial condition.
- The company Contingent Liability and Commitments could affect its financial position.
- Failures to comply with evolving data protection and privacy laws, or any cybersecurity breaches, could expose its to regulatory action, penalties, and reputational harm.
- The company directors has no prior experience in managing a listed company, which may pose challenges in complying with regulatory requirements.
- There is no listed peer companies in India with business models comparable to the company, which makes it difficult to benchmark its performance and valuation.
- Changes in technology may render the company current technologies obsolete or require its to undertake substantial capital investments, which could adversely affect the company results of operations.
- Any Penalty or demand raised by statutory authorities in future may adversely affect the financial position of the Company.
- The company may faces competition from a number of international and domestic companies, which may adversely affect its market position and business.
- Industry-related information included in this Draft Red Herring Prospectus has been derived from the CareEdge Report, which has been exclusively commissioned and paid for by the Company solely for the purposes of the Offer. This Report and the Dataset are subject to various limitations and are based upon certain assumptions that are subjective in nature.
- The company success depends largely upon the services of its Directors, Promoters and other Key Managerial Personnel and the company ability to attract and retain them and hire new talent. Demand for key managerial personnel in the industry is intense and its inability to attract and retain key managerial, may affect the business and operations of the Company.
- Failures to deal effectively with any fraudulent transactions, employee misconduct and illegal activity by Suppliers, Customers, Service providers, workers and the company employees could harm its business and reputation and expose the company to liability.
- The average cost of acquisition of Equity Shares by the company Promoter, is lower than the faces value of Equity Share.
- The company Promoter Group will continue to retain majority shareholding in its Company after this Offer which will allow it to exercise significant influence over the company.
- Any future issuance of Equity Shares may dilute your shareholdings, and sale of the Equity Shares by the company major shareholders may adversely affect the trading price of its Equity Shares.
- The Issue Price of the company Equity Shares may not be indicative of the market price of its Equity Shares after the Issue and the market price of the company Equity Shares may decline below the Issue Price and you may not be able to sell your Equity Shares at or above the Issue Price.
- The company has not identified any alternate source of funding and hence any failures or delay on its part to mobilize the required resources or any shortfall in the Issue proceeds may delay the implementation schedule.
- The Objects of the Issue for which funds are being raised has not been appraised by any bank or financial institution. Any variation between the estimation and actual expenditure as estimated by the management could result in execution delays or influence the company profitability adversely.
- The company ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements, capital expenditure and restrictive covenants in the company financing arrangements.
Q-Line Biotech Ltd Peer Comparison
Understand the company’s industry standing
Q-Line Biotech Ltd
Face Value
10
Standalone / Consolidated
Consolidated
Total Income Rs. Cr.
313.78
EPS-Basis
28.63
EPS-Diluted
28.63
NAV Per Share
---
P/E-Basic EPS
---
P/E-Diluted EPS
---
RONW(%)
23.74
Latest NAV Period
---
Latest NAV
---
How to check the allotment status of Q-Line Biotech Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 21 May 2026 & closes on 25 May 2026.
Q-Line Biotech Limited was originally incorporated as 'POCT Services Private Limited' on November 10, 2010 as a Private limited company dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand. Subsequently, the name of Company was changed to 'Q-Line Biotech Private Limited on July 23, 2021. Further, Company was converted from a private company to public company and
the name of Company was changed to 'Q-Line Biotech Limited', via fresh certificate of incorporation dated March 08, 2025 issued by Central Processing Centre.
The Company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
The Company established first manufacturing plant at Bawana, New Delhi in 2016-17. Further, during the year 2019, it incorporated POCT Science House Private Limited to engage in the business of running diagnostic laboratories. Since 2021, the facilities have been subject to regular inspections and audits by regulators, including the CDSCO, State Drug Authority, Intertek, URS Certification Limited, and other European regulatory agencies, conducted on a periodic basis. As a part of growth strategy, Company incorporated subsidiary companies namely Q-Line Iris Private Limited which are engaged in the business of Radiology & Imaging Services, which was established in the year 2023. However, during the financial year 2025, Company has sold the controlling stake in Q-Line Nutraceuticals Private Limited to focus on the core business. The Company has acquired a manufacturing plant at Lucknow, Uttar Pradesh in 2025.
Company is planning a fresh issue IPO of 70,53,200 equity shares of Rs 10 each.
Q-Line Biotech Ltd IPO will close on 25 May 2026.
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry.
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Track record of healthy financial performance.
- Experienced Promoter and Management team.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Saurabh Garg | 10191000 | 59.68 | 10191000 | 43.69 |
| 2 | Amita Garg | 3937480 | 23.06 | 3937480 | 16.88 |
| 3 | Ayush Garg | 31500 | 0.18 | 31500 | 0.14 |
| 4 | Ajay Kumar Mahanty | 750000 | 4.39 | 750000 | 3.21 |
| 5 | Abhay Agrawal | 756010 | 4.43 | 756010 | 3.24 |
| 6 | Pushplata Garg | 21000 | 0.12 | 21000 | 0.09 |
| 7 | Amit Agarwal | 31510 | 0.18 | 31510 | 0.14 |
| 8 | Shubham Garg | 31500 | 0.18 | 31500 | 0.14 |
- Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of the company raw materials, trade goods from its suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of the company products and has an adverse effect on the company business, financial condition, cash flows and results of operations.
- The company business is dependent on the sale of its products through distributors which also include the company group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of its products and could negatively impact the company business, results of operations, financial conditions and cash flows.
- The company is dependent on certain key suppliers to procure a significant portion of the company Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in its operations, which could has an adverse effect on the company business, financial condition, results of operations and cash flows.
- The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operates the company business.
- For manufacturing of its machines and reagents, the company is dependent on the agreement with the European companies, any failures to renew the agreement or entering into the agreement on the terms which is not favourable for its may impact the company business operations, financial condition and cash flows.
- The company erstwhile associate company i.e. POCT Science House Private Limited and its promoters namely Saurabh Garg and Amita Garg has been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect the company financial condition.
- The company operations is concentrated in North India, and any loss of business in such region could has an adverse effect on the company business, results of operations and financial condition.
- The Company requires a significant amount of working capital for continuing growth. Its inability to meet the company working capital requirements may adversely affect its results of operations.
- The company is subject to risks arising from exchange rate fluctuations.
- The company has experienced negative cash flows from operating activities in the last three Fiscal years and may continue to has negative cash flows in the future which could has an impact on the company business and operations.
- Fluctuations in interest rates could adversely affect the company results of operations.
- The company depends on a limited number of customers for its revenue from operations, the loss of any of these Customers individually or severally could has a material adverse effect on the company business, operations and could has impacted the company financial strength.
- The company has in the past entered into related party transactions and may continue to does so in the future.
- The company work on government tender/agreements/commitment basis with its customers who purchase or place orders with the company, also its has price agreements with the company customers. If its customers select some other vendors/competitors for their requirement, it may has adverse effect on the company business.
- The Company is governed by stricter laws for manufacturing, subject to Clinical Validation and Accuracy, research & Development for their product and services, any failures to comply with these norms and regulations could affect the company ability to effectively manufacture, test and market its products, which may has an adverse effect on the company business, results of operations and financial condition.
- The company inability to meet its obligations, including financial and other covenants under the company debt financing arrangements could adversely affect its business, financial condition, cash flows and results of operations.
- There is certain discrepancies/errors/ non-compliances noticed in some of the company corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 1956/2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate and other law could impact the reputation and financial position of the Company to that extent.
- The company is exposed to the high holding period for debtors for the finished goods supplied which can impact its working capital requirement and also impacts the company cash flows.
- Any fault or inadequacy in the company quality control, not maintaining quality standards or default in manufacturing processes may damage its reputation, business operations and may subject the company to regulatory action and expose its to litigation or other liabilities.
- The company ability to access capital at attractive costs depends on its credit ratings. Non-availability of credit ratings or a poor rating may restrict the company access to capital and thereby adversely affect its business, financial conditions, cash flows and results of operations.
- The company Promoters will be able to exercise significant influence and control over its after the Offer and may has interests that are different from or conflict with those of the company other shareholders.
- Certain of the company shareholders, Directors, Key Management Personnel and Senior Management may be interested in its Company other than in terms of remuneration and reimbursement of expenses. The company Promoters, Directors and some of its Key Managerial Personnel may has interest in entities, which are in businesses similar to the company and this may result in conflict of interest with its.
- Some of the company business operations is being conducted on leased / rented, sub lease and leave license basis. The company inability to seek renewal or extension of such leases may materially affect its business operations.
- The company inability to protect or use its intellectual property rights or comply with intellectual property rights of others may adversely affect the company business and results of operations.
- The company operations depends on the availability of skilled employees, machine operators, scientist and technicians with expertise in healthcare sector. Inability to attract or retain such personnel may affect manufacturing, R&D process which may impact financial condition, cash flow and future growth.
- The company insurance coverage may not be adequate to protect its against certain operating hazards and this may have a material adverse effect on the company business and financial conditions.
- The company business may be adversely affected by international sanctions, changes in trade policy or the imposition of non-tariff barriers, which could impact its operations and exports.
- The company has encountered challenges in meeting the designated timelines for filing statutory returns, which may subject its to penalty under the relevant laws.
- The company is exposed to risk related to disposal of the company used products, if its is not able to dispose these as per the regulatory requirement the company may faces sanctions, restrictions which may lead to loss, unstable financial position, interrupted business operation or suspension of licences.
- Any failures on the company part to effectively address investor complaints or grievances in a timely manner may expose its to regulatory action and adversely affect the company reputation, business and financial condition.
- The company Subsidiaries/Associate, Q-line Innovations Private limited and Q-line IRIS Private limited has incurred losses in Fiscal 2025, 2024 and Fiscal 2023, respectively, and may does so in the future, which could have a material adverse effect on the company business, prospects, financial condition, cash flows and results of operations.
- The company inability to accurately forecast demand for its products and manage the company inventory may has an adverse effect on its business, financial condition, cash flows and results of operations.
- The company may faces pricing pressure from its competitors, local or state government as a result of low-cost alternative products in the market, Implementation of pricing policies by the Government or other authorities at lower price that its will be able to respond adequately to such pricing pressure.
- The company inability to successfully implement some or all its business strategies in a timely manner or at all could have an adverse effect on its business.
- Delay in delivering or failures in the performance of the company contracts for whatsoever reason with its customers for supply of the company products and machines, whether on its part or on the part of carrying and forwarding ("C&F") agents, may adversely affect the company business.
- If the company fail to retain its existing or acquire additional customers in a cost-effective manner, the company business, financial condition and results of operations could be adversely affected. Further, if its try to pass on the increased costing to the company customers, its customers may choose the company competitors over its.
- The company is appointing contract labour for carrying out certain of its operations in the department of manufacturing, administration and others for which the company may be held responsible for payment of their salary and wages and statutory dues and its may also incur some legal charges if the contractor with whom the company has appointed the labour fails to pay such charges and obligations which could have an adverse effect on the company financial condition, results of operations and cash flows.
- If the company is unable to establish and maintain an effective internal controls and compliance system, its business and reputation could be adversely affected.
- Breakdown, mishaps or accidents could result in a loss or slowdown during transportation and could also cause damage to life and property.
- The company products may not provide proper results if the reagent is not as per the quality standard or the machinery is not functioning properly or for any other reasons, which may affect adversely its business operations, cash flow and profitability.
- Any actual or perceived cybersecurity, data or privacy breach could interrupt the company operations and adversely affect its reputation, brand, business, financial condition and results of operations.
- The "Q-line" brand, is critical to the company ability to acquires new users and grow its business. If the company is not able to maintain its brand or reputation the company operations could materially and adversely affect user acceptance of its platform and the company operations
- Information relating to the installed manufacturing capacity, actual production and capacity utilization of the company manufacturing facilities included in this Red Herring Prospectus is based on various assumptions and estimates and future production and capacity may vary.
- The company business is dependent on the volume of the goods its sell to achieve the optimum level of profits, if the company is not able to achieve the volumes its will end up incurring losses on account of fixed cost.
- The company is dependent on third parties for the supply of utilities, such as water, gas and electricity, at its manufacturing facilities and any disruption in the supply of such utilities could adversely affect its manufacturing operations.
- Unsecured loans taken by the company/ its Subsidiaries/ Associates can be recalled at any time.
- The Company is party to certain legal proceedings, any adverse decision in such proceedings may has a material adverse effect on its business, results of operations and financial condition.
- The company Contingent Liability and Commitments could affect its financial position.
- Failures to comply with evolving data protection and privacy laws, or any cybersecurity breaches, could expose its to regulatory action, penalties, and reputational harm.
- The company directors has no prior experience in managing a listed company, which may pose challenges in complying with regulatory requirements.
- There is no listed peer companies in India with business models comparable to the company, which makes it difficult to benchmark its performance and valuation.
- Changes in technology may render the company current technologies obsolete or require its to undertake substantial capital investments, which could adversely affect the company results of operations.
- Any Penalty or demand raised by statutory authorities in future may adversely affect the financial position of the Company.
- The company may faces competition from a number of international and domestic companies, which may adversely affect its market position and business.
- Industry-related information included in this Draft Red Herring Prospectus has been derived from the CareEdge Report, which has been exclusively commissioned and paid for by the Company solely for the purposes of the Offer. This Report and the Dataset are subject to various limitations and are based upon certain assumptions that are subjective in nature.
- The company success depends largely upon the services of its Directors, Promoters and other Key Managerial Personnel and the company ability to attract and retain them and hire new talent. Demand for key managerial personnel in the industry is intense and its inability to attract and retain key managerial, may affect the business and operations of the Company.
- Failures to deal effectively with any fraudulent transactions, employee misconduct and illegal activity by Suppliers, Customers, Service providers, workers and the company employees could harm its business and reputation and expose the company to liability.
- The average cost of acquisition of Equity Shares by the company Promoter, is lower than the faces value of Equity Share.
- The company Promoter Group will continue to retain majority shareholding in its Company after this Offer which will allow it to exercise significant influence over the company.
- Any future issuance of Equity Shares may dilute your shareholdings, and sale of the Equity Shares by the company major shareholders may adversely affect the trading price of its Equity Shares.
- The Issue Price of the company Equity Shares may not be indicative of the market price of its Equity Shares after the Issue and the market price of the company Equity Shares may decline below the Issue Price and you may not be able to sell your Equity Shares at or above the Issue Price.
- The company has not identified any alternate source of funding and hence any failures or delay on its part to mobilize the required resources or any shortfall in the Issue proceeds may delay the implementation schedule.
- The Objects of the Issue for which funds are being raised has not been appraised by any bank or financial institution. Any variation between the estimation and actual expenditure as estimated by the management could result in execution delays or influence the company profitability adversely.
- The company ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements, capital expenditure and restrictive covenants in the company financing arrangements.
The Issue type of Q-Line Biotech Ltd is Book Building - SME.
The minimum application for shares of Q-Line Biotech Ltd is 800.
The total shares issue of Q-Line Biotech Ltd is 6253200.
Initial public offer of upto 62,53,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Q-Line Biotech Limited ("the Company" or "QLBL" or "the Issuer") at an issue price of Rs. 343 per equity share (including share premium of Rs. 333 per equity share) for cash, aggregating up to Rs. 214.48 Crores ("Public Issue") out of which 3,13,200 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating Rs. 10.74 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 59,40,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating upto Rs. 203.74 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.81% and 25.46% respectively of the post- issue paid-up equity share capital of the company.
The company, in consultation with the book running lead managers, may consider a pre-ipo placement of up to 8,00,000 equity shares for cash consideration ("pre-ipo placement") prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the book running lead managers. If the pre-ipo placement is undertaken, the number of equity shares issued pursuant to the pre-ipo placement shall be reduced from the issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended ("scrr").
Price Band: Rs. 343 per equity share of face value Rs. 10/- each.
The floor price (Rs.343) is 34.3 times of the face value of the equity shares.
Bids can be made for a minimum of 800 equity shares and in multiples of 400 equity shares thereafter.